

## CABLES2 Antibody (Center)

Affinity Purified Rabbit Polyclonal Antibody (Pab)

Catalog # AP20448c

### Product Information

---

<b>Application</b>	WB, E
<b>Primary Accession</b>	<a href="#">Q9BTV7</a>
<b>Other Accession</b>	<a href="#">Q8K3M5</a>
<b>Reactivity</b>	Human, Mouse
<b>Host</b>	Rabbit
<b>Clonality</b>	Polyclonal
<b>Isotype</b>	Rabbit IgG
<b>Calculated MW</b>	52235
<b>Antigen Region</b>	182-210

### Additional Information

---

<b>Gene ID</b>	81928
<b>Other Names</b>	CDK5 and ABL1 enzyme substrate 2, Interactor with CDK3 2, Ik3-2, CABLES2, C20orf150
<b>Target/Specificity</b>	This CABLES2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 182-210 amino acids from the Central region of human CABLES2.
<b>Dilution</b>	WB~~1:1000 E~~Use at an assay dependent concentration.
<b>Format</b>	Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.
<b>Storage</b>	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
<b>Precautions</b>	CABLES2 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.

### Protein Information

---

<b>Name</b>	CABLES2
<b>Synonyms</b>	C20orf150
<b>Function</b>	Unknown. Probably involved in G1-S cell cycle transition.

## Background

---

Unknown. Probably involved in G1-S cell cycle transition.

## References

---


Deloukas P., et al. Nature 414:865-871(2001).

Daub H., et al. Mol. Cell 31:438-448(2008).

Oppermann F.S., et al. Mol. Cell. Proteomics 8:1751-1764(2009).

## Images

---



CABLES2 Antibody (Center) (Cat. #AP20448c) western blot analysis in PC-3 cell line and mouse brain, testis and liver lysates (35ug/lane). This demonstrates the CABLES2 antibody detected the CABLES2 protein (arrow).

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.